Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

sandoz s.r.o., praha array - 14895 sodnÁ sŮl montelukastu - potahovaná tableta - 10mg - montelukast

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

zentiva, k.s., praha array - 14895 sodnÁ sŮl montelukastu - Žvýkací tableta - 4mg - montelukast

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

zentiva, k.s., praha array - 14895 sodnÁ sŮl montelukastu - Žvýkací tableta - 5mg - montelukast

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

vivax pharmaceuticals, s.r.o., povážská bystrica array - 810 lyofilizovanÝ lactobacillus acidophilus; 2193 estriol - vaginální tableta - 50mg/0,03mg - estriol

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

zentiva, k.s., praha array - 10905 zolpidem-tartarÁt - potahovaná tableta - 10mg - zolpidem

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

n.v. organon, oss array - 14895 sodnÁ sŮl montelukastu - potahovaná tableta - 10mg - montelukast

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

heaton k.s., praha array - 578 ethinylestradiol; 2141 cyproteron-acetÁt - obalená tableta - 2mg/0,035mg - cyproteron a estrogen

Česká republika - čeština - USKVBL (Ústav Pro Státní Kontrolu Veterinárních Biopreparátů A Léčiv)

bb pharma a.s. - sodný, glycerofosforečnan - injekční roztok - elektrolyt řešení - koně, kozy, kožešinová zvířata, ovce, prasata, skot, psi

Evropská unie - čeština - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artritida, revmatoidní - imunosupresiva - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Evropská unie - čeština - EMA (European Medicines Agency)

aziende chimiche riunite angelini francesco s.p.a. - lurasidon - schizofrenie - psycholeptika - léčba schizofrenie u dospělých ve věku 18 let a více.